Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Account Payables (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Change in Account Payables for 11 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 504.03% year-over-year to $5.8 million, compared with a TTM value of $2.2 million through Dec 2025, up 193.1%, and an annual FY2025 reading of $2.2 million, up 193.1% over the prior year.
  • Change in Account Payables was $5.8 million for Q4 2025 at Tandem Diabetes Care, up from -$9.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $10.5 million in Q1 2021 and bottomed at -$9.3 million in Q3 2025.
  • Average Change in Account Payables over 3 years is $1.2 million, with a median of -$898000.0 recorded in 2025.
  • Peak annual rise in Change in Account Payables hit 504.03% in 2025, while the deepest fall reached 682.06% in 2025.
  • Year by year, Change in Account Payables stood at $10.5 million in 2021, then plummeted by 113.67% to -$1.4 million in 2024, then soared by 504.03% to $5.8 million in 2025.
  • Business Quant data shows Change in Account Payables for TNDM at $5.8 million in Q4 2025, -$9.3 million in Q3 2025, and -$898000.0 in Q2 2025.